Insider · CIK 0001646558

Colleran David

Reports to the SEC for 2 companies · BEDFORD, MA

sec.gov

Transactions

Companies

Filings

CIK

0001646558

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-15	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−6,449 sh	—	—	6,448
2026-03-15	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+6,449 sh	—	—	69,463
2026-03-15	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,893 sh	$14.20	−$26.9K	67,570
2026-03-14	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−9,388 sh	—	—	18,777
2026-03-14	ANIKAnika Therapeutics, Inc.A Award	EVP, General Counsel, Corp Sec	AAward	+4,694 sh	—	—	67,182
2026-03-14	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+9,388 sh	—	—	62,488
2026-03-14	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−4,168 sh	$14.20	−$59.2K	63,014
2026-03-09	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,919 sh	$14.96	−$28.7K	53,100
2026-03-09	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+5,465 sh	—	—	55,019
2026-03-09	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−5,465 sh	—	—	0
2025-03-17	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−6,448 sh	—	—	12,897
2025-03-17	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+6,448 sh	—	—	49,847
2025-03-17	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,893 sh	$15.91	−$30.1K	47,954
2025-03-14	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitA Award	EVP, General Counsel, Corp Sec	AAward	+13.7K sh	—	—	13,669
2025-03-14	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitA Award	EVP, General Counsel, Corp Sec	AAward	+28.2K sh	—	—	28,165
2025-03-11	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−7,663 sh	—	—	0
2025-03-11	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−2,250 sh	$16.79	−$37.8K	43,399
2025-03-11	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+7,663 sh	—	—	45,649
2025-03-10	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−5,465 sh	—	—	5,465
2025-03-10	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,604 sh	$16.62	−$26.7K	37,986
2025-03-10	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+5,465 sh	—	—	39,590
2024-03-15	ANIKAnika Therapeutics, Inc. · Stock Option (Right to Buy)A Award	EVP, General Counsel, Corp Sec	AAward	+46.9K sh	—	—	46,875
2024-03-15	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitA Award	EVP, General Counsel, Corp Sec	AAward	+19.3K sh	—	—	19,345
2024-03-11	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,605 sh	$25.42	−$40.8K	27,583
2024-03-11	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−7,662 sh	—	—	7,663
2024-03-11	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−5,465 sh	—	—	10,930
2024-03-11	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−3,682 sh	—	—	0
2024-03-11	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−2,250 sh	$25.79	−$58K	32,995
2024-03-11	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+7,662 sh	—	—	35,245
2024-03-11	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+5,465 sh	—	—	29,188
2024-03-11	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,081 sh	$25.42	−$27.5K	23,723
2024-03-11	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+3,682 sh	—	—	24,804
2023-03-10	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+7,663 sh	—	—	22,538
2023-03-10	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−7,663 sh	—	—	15,325
2023-03-10	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−2,250 sh	$26.10	−$58.7K	20,288
2023-03-09	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−3,683 sh	—	—	3,682
2023-03-09	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+3,683 sh	—	—	15,956
2023-03-09	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,081 sh	$26.91	−$29.1K	14,875
2023-03-09	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitA Award	EVP, General Counsel, Corp Sec	AAward	+16.4K sh	—	—	16,395
2023-03-09	ANIKAnika Therapeutics, Inc. · Stock Option (Right to Buy)A Award	EVP, General Counsel, Corp Sec	AAward	+35.8K sh	—	—	35,790
2023-03-04	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+2,500 sh	—	—	13,007
2023-03-04	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−2,500 sh	—	—	0
2023-03-04	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−734 sh	$31.59	−$23.2K	12,273
2022-05-11	ANIKAnika Therapeutics, Inc.P Purchase	EVP, General Counsel, Corp Sec	PPurchase	+1,500 sh	$21.37	+$32.1K	9,867
2022-03-14	ANIKAnika Therapeutics, Inc.P Purchase	EVP, General Counsel, Corp Sec	PPurchase	+1,500 sh	$26.65	+$40K	8,367
2022-03-11	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitA Award	EVP, General Counsel, Corp Sec	AAward	+23K sh	—	—	22,988
2022-03-11	ANIKAnika Therapeutics, Inc. · Stock Option (Right to Buy)A Award	EVP, General Counsel, Corp Sec	AAward	+35.9K sh	—	—	35,864
2022-03-09	ANIKAnika Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	−3,682 sh	—	—	7,365
2022-03-09	ANIKAnika Therapeutics, Inc.M Exercise/Conversion	EVP, General Counsel, Corp Sec	MExercise/Conversion	+3,682 sh	—	—	7,948
2022-03-09	ANIKAnika Therapeutics, Inc.F Tax Payment	EVP, General Counsel, Corp Sec	FTax Payment	−1,081 sh	$26.22	−$28.3K	6,867

Recent filings

Accepted (ET)
Mar 174
Colleran David0001193125-26-111511
SEC(opens sec.gov)
Mar 114
Colleran David0001193125-26-102240
SEC(opens sec.gov)
Mar 184
Colleran David0001171843-25-001532
SEC(opens sec.gov)
Mar 134
Colleran David0001171843-25-001468
SEC(opens sec.gov)
Mar 114
Colleran David0001171843-25-001405
SEC(opens sec.gov)

Companies

Address

C/O ANIKA THERAPEUTICS, INC. 32 WIGGINS AVENUE

BEDFORD, MA, 01730